Aberrant CDKN1A transcriptional response associates with abnormal sensitivity to radiation treatment.
Authors
Badie, ChristopheDziwura, S
Raffy, C
Tsigani, Theodora
Alsbeih, G
Moody, J
Finnon, Paul
Levine, Edward
Scott, David A
Bouffler, Simon
Affiliation
Radiation Effects Department, Health Protection Agency, Centre for Radiation Chemical and Environmental Hazards, Radiation Protection Division, Chilton, Didcot, Oxfordshire OX11 ORQ, UK. christophe.badie@hpa.org.ukIssue Date
2008-06-03
Metadata
Show full item recordAbstract
Normal tissue reactions to radiation therapy vary in severity among patients and cannot be accurately predicted, limiting treatment doses. The existence of heritable radiosensitivity syndromes suggests that normal tissue reaction severity is determined, at least in part, by genetic factors and these may be revealed by differences in gene expression. To test this hypothesis, peripheral blood lymphocyte cultures from 22 breast cancer patients with either minimal (11) or very severe acute skin reactions (11) have been used to analyse gene expression. Basal and post-irradiation expression of four radiation-responsive genes (CDKN1A, GADD45A, CCNB1, and BBC3) was determined by quantitative real-time PCR in T-cell cultures established from the two patient groups before radiotherapy. Relative expression levels of BBC3, CCNB1, and GADD45A 2 h following 2 Gy X-rays did not discriminate between groups. However, post-irradiation expression response was significantly reduced for CDKN1A (P<0.002) in severe reactors compared to normal. Prediction of reaction severity of approximately 91% of individuals sampled was achieved using this end point. Analysis of TP53 Arg72Pro and CDKN1A Ser31Arg single nucleotide polymorphisms did not show any significant association with reaction sensitivity. Although these results require confirmation and extension, this study demonstrates the possibility of predicting the severity of acute skin radiation toxicity in simple tests.Citation
Aberrant CDKN1A transcriptional response associates with abnormal sensitivity to radiation treatment. 2008, 98 (11):1845-51 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/sj.bjc.6604381PubMed ID
18493234Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/sj.bjc.6604381
Scopus Count
Related articles
- Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients.
- Authors: Tan XL, Popanda O, Ambrosone CB, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J
- Issue date: 2006 Jun
- Effector genes altered in MCF-7 human breast cancer cells after exposure to fractionated ionizing radiation.
- Authors: Li Z, Xia L, Lee LM, Khaletskiy A, Wang J, Wong JY, Li JJ
- Issue date: 2001 Apr
- Combining CDKN1A gene expression and genome-wide SNPs in a twin cohort to gain insight into the heritability of individual radiosensitivity.
- Authors: Zyla J, Kabacik S, O'Brien G, Wakil S, Al-Harbi N, Kaprio J, Badie C, Polanska J, Alsbeih G
- Issue date: 2019 Jul
- Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
- Authors: Popanda O, Edler L, Waas P, Schattenberg T, Butkiewicz D, Muley T, Dienemann H, Risch A, Bartsch H, Schmezer P
- Issue date: 2007 Jan
- Evidence that individual variations in TP53 and CDKN1A protein responsiveness are related to inherent radiation sensitivity.
- Authors: Alsbeih G, Torres M, Al-Harbi N, Al-Buhairi M
- Issue date: 2007 Jan